文献速递骨显像与常规 SPECT肿瘤 PET/CT心脏核医学

18F-氟化钠PET/CT应用进展

18F-Fluoride PET/CT-Updates.
PubMed 文献 · Semin Nucl Med · 2024-10-11

氟化钠-18于20世纪40年代开始生产,1962年首次被描述为骨显像剂,后因常规骨显像成本低而沉寂;三维全身PET/CT出现后氟化钠PET/CT重新兴起。该显像剂在肿瘤与非肿瘤性骨关节病变中具有更高的灵敏度和特异度,可分子水平显示全骨骼骨代谢重塑并与解剖信息融合。本文综述其在肿瘤、骨科、炎症、心血管疾病及治疗反应评估中的临床应用进展。

要点

  • 氟化钠-18于1962年首次被描述为骨显像剂,后因常规骨显像低成本而长期未广泛应用。
  • 常规骨显像灵敏度高但特异度不足,氟化钠PET/CT可提高骨病变诊断的特异度和准确度。
  • 氟化钠PET/CT在肿瘤及骨科、炎症、心血管等良性病变和治疗反应评估中有临床应用更新。

核心结论

  • 氟化钠PET/CT在肿瘤与非肿瘤性骨关节病变中均具有更高的灵敏度和特异度,并可分子水平显示全身骨骼骨代谢重塑。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 氟化钠-18于20世纪40年代开始生产,1962年首次被临床描述为骨显像剂,后因常规骨显像的发展而应用沉寂。
  • 常规骨显像数十年来是识别成骨性骨转移最常用的核医学技术,尤其用于前列腺癌和乳腺癌,也用于骨科良性骨病。
  • 常规骨显像灵敏度高但缺乏足够特异度;三维全身PET/CT出现后氟化钠PET/CT重新兴起。
  • 氟化钠PET/CT可提供全骨骼骨代谢重塑的分子水平精确视图,并结合解剖信息提高诊断特异度和准确度。

关键数值与推荐

  • 本文为综述,未汇总具体诊断标准或数值阈值。

临床怎么用

  • 本文为综述,未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sodium Fluoride-18 production started in the 1940s and was described clinically for the first time in 1962 as a bone-imaging agent. However, its use became dormant with the development of conventional bone scintigraphy, especially due to its low cost. Conventional bone scintigraphy has been the most utilized Nuclear Medicine technique for identifying osteoblastic bone metastases, especially in prostate and breast cancers for decades and is also employed to identify benign bone disease, especially in the orthopedic setting. While bone scintigraphy is highly sensitive, it lacks adequate specificity. With the advent of high-quality 3D Whole-Body Positron Emission Tomography combined with computed tomography (PET/CT), images, Sodium Fluoride-18 imaging with PET/CT (Fluoride PET/CT) re-emerged. This PET/CT bone-imaging agent provides higher sensitivity and specificity to detect bone lesions in both the oncological scenario as well as to identify benign bone and joint disorders. PET/CT bone-imaging provides a precise view of the bone metabolism remodeling processes at a molecular level, throughout the skeleton, and combines anatomical information, enhancing diagnostic specificity and accuracy. This article review will explore the updates on clinical applications of Fluoride PET/CT in oncology and benign conditions encompassing orthopedic, inflammatory and cardiovascular conditions and treatment response assessment.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nogueira-Lima E, Alves T, Etchebehere E, et al. 18F-Fluoride PET/CT-Updates. Semin Nucl Med. 2024. PMID: 39393951. doi:10.1053/j.semnuclmed.2024.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。